Barcelona signs Marcus Rashford from Man United on a season-long loan
The England forward, who was once considered among Europe's top talents, has seen his career stall in recent years after falling out of favor at United and ending last season on loan at Aston Villa.
The 27-year-old Rashford will join a Barcelona attack that includes young star Lamine Yamal, Brazil international Raphinha and veteran striker Robert Lewandowski.
Rashford had arrived in Barcelona on Sunday to sign his contract. He had already met his teammates and reportedly trained with the group on Tuesday.
Financial details were not immediately disclosed. Spanish media said the agreement with United would give Barcelona an option to buy Rashford for about 30 million euros (USD 35 million).
Spanish champion Barcelona had looked set to sign Spain forward Nico Williams this offseason until he agreed a 10-year deal to stay at Athletic Bilbao earlier this month. That opened the door for Rashford to make the switch.
Potent attack
Barcelona had the best attack in Spanish soccer and one of the most prolific across Europe last season, but had been trying to add another piece to the front line to go along with Yamal, Raphinha and Lewandowski.
📞 "Yeah… It's official."
Rashford follows in Lineker's footsteps. pic.twitter.com/ZvbnDAtbax — FC Barcelona (@FCBarcelona) July 23, 2025
The trio helped the club score 102 goals as it won the Spanish league title, 24 goals more than runner-up Real Madrid. The Catalan club also led the Champions League in goals with 43, five more than champion Paris Saint-Germain, before being eliminated by Inter Milan in the semifinals.
What went wrong at United?
Rashford had progressed through United's famed academy that produced greats like Ryan Giggs and David Beckham. He made 429 appearances, scored 138 goals and helped United win five major trophies, including two FA Cups and the Europa League.
But he struggled to consistently live up to the hype that surrounded him when he burst onto the scene as a teenager in 2016 — only managing 20 goals or more in three seasons. In his last two seasons at United he scored a combined 15 goals and added another four in 17 games on loan at Villa.
But Rashford's ability has rarely been called into question and he recently earned a recall to the England squad under new coach Thomas Tuchel, putting him in contention for next year's World Cup if the national team qualifies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Gold declines Rs 500 to Rs 98,020 per 10 gram; silver plunges Rs 1,000 per kg
Gold prices slid for the fourth consecutive session and ended Rs 500 lower at Rs 98,020 per 10 grams in the national capital on Monday due to unabated selling by stockists following a trade deal between the US and the EU, which dampened the safe-haven demand. According to the All India Sarafa Association, the precious metal of 99.9 per cent purity ended at Rs 98,520 per 10 grams, down by Rs 600 on Saturday. Explore courses from Top Institutes in Please select course: Select a Course Category Technology Leadership Operations Management Cybersecurity Artificial Intelligence Degree Data Science Others Product Management Design Thinking Digital Marketing Management Data Analytics Data Science Finance Project Management others Public Policy Healthcare MCA MBA CXO healthcare Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Discover Nikoo Homes from ₹1.2 Cr* Nikoo Homes Sadahalli Learn More Undo In the national capital, gold of 99.5 per cent purity extended its losing run for the fourth straight day, by declining Rs 500 to Rs 97,750 per 10 grams (inclusive of all taxes) on Monday. It had finished at Rs 98,250 per 10 grams in the previous market session. In addition, silver prices depreciated Rs 1,000 to Rs 1,13,000 per kilogram (inclusive of all taxes) on Monday. The white metal had closed at Rs 1,14,000 per kg on Saturday. Meanwhile, spot gold and silver traded flat at USD 3,337.95 and USD 38.17 per ounce, respectively, in the global markets. Live Events "Gold traded in a positive but flat range near USD 3,335 per ounce, as strength in the dollar index limited gains last week," Jateen Trivedi, VP Research Analyst, Commodity and Currency, LKP Securities, said. The US has announced a trade deal with the European Union (EU), which includes a 15 per cent tariff on most European goods entering the American market alongside the 27-nation block's commitment to invest hundreds of billions of dollars in American industry. This agreement mirrors last week's US-Japan trade pact. "Investors will closely track upcoming US macroeconomic data, including jobless claims and Q2 GDP figures during the week," Abans Financial Services ' Chief Executive Officer Chintan Mehta said. According to Saumil Gandhi, Senior Analyst, Commodities at HDFC Securities, the price of gold remains stagnant, as bulls remain cautious amid trade optimism and a stronger US dollar . Gandhi further said that bullion prices declined last week due to a drop in demand for safe haven assets amid an easing in tariff concerns. Additionally, President Donald Trump alleviated market worries about the US Federal Reserve's independence by downplaying tensions with Fed Chair Jerome Powell. "Both factors contributed to the rise in the US dollar, which has risen for the third consecutive day and is negatively impacting precious metal prices," he added.
News18
an hour ago
- News18
Gold declines Rs 500 to Rs 98,020/10 g; silver plunges Rs 1,000
New Delhi, Jul 28 (PTI) Gold prices slid for the fourth consecutive session and ended Rs 500 lower at Rs 98,020 per 10 grams in the national capital on Monday due to unabated selling by stockists following a trade deal between the US and the EU, which dampened the safe-haven demand. According to the All India Sarafa Association, the precious metal of 99.9 per cent purity ended at Rs 98,520 per 10 grams, down by Rs 600 on Saturday. In the national capital, gold of 99.5 per cent purity extended its losing run for the fourth straight day, by declining Rs 500 to Rs 97,750 per 10 grams (inclusive of all taxes) on Monday. It had finished at Rs 98,250 per 10 grams in the previous market session. In addition, silver prices depreciated Rs 1,000 to Rs 1,13,000 per kilogram (inclusive of all taxes) on Monday. The white metal had closed at Rs 1,14,000 per kg on Saturday. Meanwhile, spot gold and silver traded flat at USD 3,337.95 and USD 38.17 per ounce, respectively, in the global markets. 'Gold traded in a positive but flat range near USD 3,335 per ounce, as strength in the dollar index limited gains last week," Jateen Trivedi, VP Research Analyst, Commodity and Currency, LKP Securities, said. The US has announced a trade deal with the European Union (EU), which includes a 15 per cent tariff on most European goods entering the American market alongside the 27-nation block's commitment to invest hundreds of billions of dollars in American industry. This agreement mirrors last week's US-Japan trade pact. 'Investors will closely track upcoming US macroeconomic data, including jobless claims and Q2 GDP figures during the week," Abans Financial Services' Chief Executive Officer Chintan Mehta said. According to Saumil Gandhi, Senior Analyst, Commodities at HDFC Securities, the price of gold remains stagnant, as bulls remain cautious amid trade optimism and a stronger US dollar. Gandhi further said that bullion prices declined last week due to a drop in demand for safe haven assets amid an easing in tariff concerns. Additionally, President Donald Trump alleviated market worries about the US Federal Reserve's independence by downplaying tensions with Fed Chair Jerome Powell. 'Both factors contributed to the rise in the US dollar, which has risen for the third consecutive day and is negatively impacting precious metal prices," he added. PTI HG HVA view comments First Published: July 28, 2025, 17:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Mint
an hour ago
- Mint
Jiangsu Hengrui Pharma stock spikes 10% to 4-year high on drug development deal with GSK – here's what the company does
Shares of Jiangsu Hengrui Pharmaceuticals Company, a Chinese pharmaceutical firm, jumped 10% to hit a 4-year high of 61-yuan, equivalent to USD 9.62 on the Shanghai Stock Exchange (SSE), after the company announced that it had agreed to license the global rights of its HRS-9821 drug and 11 other programs to GlaxoSmithKline Intellectual Property (GSK). The programs were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I), and Oncology pipeline, having been assessed for their potential best-in-class or first-in-class profiles. The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong, Macau, and Taiwan) for a potential best-in-class PDE3/4 inhibitor (HRS-9821), which is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, regardless of background therapy, GSK said in its filing on Monday. The British pharmaceutical giant added that HRS-9821 supports its ambition to treat patients across the widest spectrum of COPD, including those who experience continued dyspnea (shortness of breath) or are unlikely to receive inhaled corticosteroids or biologics, based on their disease profile. The agreements also feature a pioneering, large-scale collaboration to develop up to 11 additional programs besides HRS-9821, each with its own financial structure. Hengrui Pharma will lead the development of these programs up to the completion of Phase I trials, including trials involving patients outside of China. GSK will have the exclusive option to further develop and commercialize each program worldwide (excluding mainland China, Hong Kong, Macau, and Taiwan) at the end of Phase I or earlier, at its discretion, and will also have program substitution rights. GSK has agreed to pay $500 million in upfront fees across the agreements, including for the license of the PDE3/4 program. The potential total value of future success-based development, regulatory, and commercial milestone payments to Hengrui Pharma could reach approximately $12 billion if all programs are optioned and all milestones are met. Additionally, Hengrui Pharma will be eligible for tiered royalties on global product net sales (excluding mainland China, Hong Kong, Macau, and Taiwan). The license to HRS-9821 remains subject to customary conditions, including regulatory clearance under the Hart-Scott-Rodino Act in the United States. Tony Wood, Chief Scientific Officer at GSK, said, 'We're delighted to announce these exciting agreements with Hengrui Pharma, which complement our already extensive pipeline. This deal reflects our strategic investment in programs that address validated targets, increasing the likelihood of success, while giving us the option to advance the assets with the greatest potential for patient impact.' Founded in 1970, Hengrui Pharma is a global pharmaceutical company dedicated to research, development, and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D network of 14 centers and over 5,500 professionals, Hengrui's therapeutic focus includes oncology, metabolic and cardiovascular diseases, immunological and respiratory disorders, and neuroscience. To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
